Income Statement Vector Science and Therapeutics Corp.

Stocks

Market Closed - Toronto S.E. 01:29:55 07/10/2026 am IST			5-day change	1st Jan Change
1.750 ^CAD	-7.89%		-6.42%	+3,400.00%

24/08	Vector Science Starts Manufacturing Pharma-Grade Peptides	MT
24/08	Vector Science & Therapeutics Increases Peptide Manufacturing Capacity At Lyogenesis Facility	CI

8a6e36cb325eb47e70.MYdFtsijXTmog0MmrNci_QXAofccCjNoK5xhgDyI9nc.YOAv0Ir0Gl3q1CVP44RYkDSk6KVQZUE5ZewxskjDjB9A0RbXjdc5f8PyIA

Published financial data: VECTOR SCIENCE AND THERAPEUTICS CORP.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: August	2024 (USD)	2025 (USD)
Cost of Goods Sold, Total	-	2L
Gross Profit	-	-2L
Selling General & Admin Expenses, Total	-	3L
Other Operating Expenses, Total	-	3L
Operating Income	-	-5L
Currency Exchange Gains (Loss)	-	-14.75T
Other Non Operating Income (Expenses)	-	-4L
EBT, Excl. Unusual Items	-	-9L
EBT, Incl. Unusual Items	-	-9L
Earnings From Continuing Operations	-	-9L
Net Income to Company	-	-9L
Net Income - (IS)	-	-9L
Net Income to Common Incl Extra Items	-	-9L
Net Income to Common Excl. Extra Items	-	-9L
Per Share Items
Net EPS - Basic	-	-0.13
Basic EPS - Continuing Operations	-	-0.13
Basic Weighted Average Shares Outstanding	-	69.52L
Net EPS - Diluted	-	-0.13
Diluted EPS - Continuing Operations	-	-0.13
Diluted Weighted Average Shares Outstanding	-	69.52L
Normalized Basic EPS	-	-0.08
Normalized Diluted EPS	-	-0.08
Supplemental Items
EBITA	-	-5L
EBIT	-	-5L
Normalized Net Income	-	-6L
Supplemental Operating Expense Items
Marketing Expenses	-	11.64T
Selling and Marketing Expenses	-	11.64T
General and Administrative Expenses	-	3L
Research And Development Expense From Footnotes	-	2L

Fiscal Period: August	2024 (USD)	2025 (USD)
Assets
Cash And Equivalents	-	28.82L
Total Cash And Short Term Investments	-	28.82L
Other Receivables	600	-
Total Receivables	600	-
Prepaid Expenses	-	1L
Total Current Assets	600	29.82L
Other Intangibles, Total	-	23.48T
Total Assets	600	30.05L
Liabilities
Accounts Payable, Total	-	2L
Other Current Liabilities	-	22.72T
Total Current Liabilities	-	3L
Other Non Current Liabilities	-	10.28L
Total Liabilities	-	12.8L
Common Stock, Total	600	25.08L
Retained Earnings	-	-9L
Comprehensive Income and Other	-	1L
Total Common Equity	600	17.25L
Total Equity	600	17.25L
Total Liabilities And Equity	600	30.05L
Supplemental Items
ECS Total Shares Outstanding on Filing Date	-	69.52L
ECS Total Common Shares Outstanding	-	69.52L
Book Value / Share	-	0.25
Tangible Book Value	600	17.01L
Tangible Book Value Per Share	-	0.24
Total Debt	0	0
Net Debt	-	-28.82L
Account Code - Inventory Valuation	-	3

Fiscal Period: August	2024 (USD)	2025 (USD)
Net Income	-	-9L
Other Operating Activities, Total	-	-27.95T
Change In Accounts Payable	-	3L
Change in Other Net Operating Assets	-	-1L
Cash from Operations	-	-8L
Sale (Purchase) of Intangible assets	-	-23.47T
Cash from Investing	-	-23.47T
Issuance of Common Stock	800	39.56L
Other Financing Activities, Total	-800	-3L
Cash from Financing	0	36.79L
Net Change in Cash	-	28.82L

Fiscal Period: August	2024 (USD)	2025 (USD)
Profitability
Return on Assets	-	-19.01
Return on Total Capital	-	-33.12
Return On Equity %	-	-104.1
Return on Common Equity	-	-104.1
Short Term Liquidity
Current Ratio	-	11.81
Quick Ratio	-	11.41
Operating Cash Flow to Current Liabilities	-	-3.07
Long Term Solvency
Total Liabilities / Total Assets	-	42.61
Growth Over Prior Year
Total Assets, 1 Yr. Growth %	-	5L
Tangible Book Value, 1 Yr. Growth %	-	3L
Common Equity, 1 Yr. Growth %	-	3L